#Italy #Milan #Newronika #AlphaDBS #Parkinson

Newronika Achieves Milestone with CE Mark Approval for AlphaDBS

In a significant advancement for patients suffering from Parkinson's disease, Newronika, a leader in neuromodulation technologies, has announced that its cutting-edge system, AlphaDBS, has received CE mark approval. This approval paves the way for marketing AlphaDBS across Europe, offering new hope and therapeutic options for those affected by this progressive neurological disorder.

What is AlphaDBS?

AlphaDBS represents a new generation of deep brain stimulation (DBS) technology that operates on a closed-loop system. Unlike traditional DBS devices that provide constant stimulation at fixed settings, AlphaDBS utilizes real-time brain signals to adapt the stimulation dynamically. This innovative approach is a leap forward in how DBS can be personalized for individual patients, optimizing treatment effectiveness while minimizing unwanted side effects.

Impact on Patients with Parkinson's Disease

Deep brain stimulation has proven to be an effective therapy for managing various Parkinson's symptoms, and its usage has expanded to addressing other neurological conditions as well. Hundreds of thousands of DBS devices have been successfully implanted worldwide, helping patients manage issues like Parkinson's disease, dystonia, essential tremors, and obsessive-compulsive disorder (OCD).

The traditional method of DBS relies on set stimulation patterns, which can lead to challenges such as the need for frequent programming adjustments and sometimes undesirable side effects. AlphaDBS rises to this challenge by continuously monitoring the patient's brain activity and automatically adjusting stimulation levels to ensure optimal symptom management. This not only enhances patient comfort but also improves the overall quality of life, enabling many to experience symptom relief more consistently.

Technical Insights into AlphaDBS

According to Lorenzo Rossi, Chief Technology Officer and co-founder of Newronika, the CE mark approval for AlphaDBS is a landmark achievement, validating the company's commitment to developing truly adaptive neuromodulation solutions. Clinical studies supporting this technology demonstrate enhanced patient outcomes; participants receiving adaptive stimulation report reduced symptoms duration and fewer side effects compared to traditional methods.

With this regulatory milestone under their belt, Newronika is poised to launch AlphaDBS across various European markets in 2025.

Moreover, the company is broadening its global reach. Recently, it secured an experimental device exemption (IDE) from the U.S. Food and Drug Administration (FDA), which allows them to initiate pivotal clinical trials in the United States.

Looking Ahead: The Future of Neuromodulation

Newronika, a spin-off from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and the University of Milan, is at the forefront of advancing deep brain stimulation technology. Their adaptive platform is revolutionary, as it incorporates patient-specific data in real-time to tailor therapies effectively, moving past conventional boundaries of treatment.

As the company gears up for a commercial launch and expands its innovative solutions in neuromodulation, AlphaDBS sets a new standard not only for Parkinson's disease therapy but potentially for any condition treated with neurostimulation.

For more information about Newronika and its groundbreaking technologies, please visit www.newronika.com or follow the company on LinkedIn.